ACADIA Pharmaceuticals Down Over 8%, on Pace for Largest Percent Decrease Since September 2025 -- Data Talk
Dow Jones2026/09/24 15:02ACADIA Pharmaceuticals Inc. (ACAD) is currently at $23.24, down $2.20 or 8.63%
--Would be lowest close since June 23, 2026, when it closed at $22.60
--On pace for largest percent decrease since Sept. 24, 2025, when it fell 9.92%
--Currently down five of the past six days
--Currently down two consecutive days; down 12.02% over this period
--Worst two day stretch since the two days ending Sept. 24, 2025, when it fell 13.33%
--Down 19.63% month-to-date; on pace for worst month since March 2024, when it fell 20.44%
--Down 13.01% year-to-date
--Down 59.24% from its all-time closing high of $57.00 on July 7, 2020
--Up 9.55% from 52 weeks ago (Sept. 25, 2025), when it closed at $21.21
--Down 23.99% from its 52-week closing high of $30.57 on Aug. 25, 2026
--Up 15.83% from its 52-week closing low of $20.06 on Oct. 13, 2025
--Traded as low as $21.97; lowest intraday level since June 22, 2026, when it hit $21.59
--Down 13.61% at today's intraday low; largest intraday percent decrease since Sept. 24, 2025, when it fell as much as 15.17%
All data as of 11:00:17 AM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 24, 2026 11:02 ET (15:02 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank Group’s credit risk rises to a four-year high, as AI bets and acquisition rumors heighten leverage concerns
Due to increased market concerns over AI-related financing and potential large-scale acquisitions, SoftBank Group's credit risk indicator—the credit default swap (CDS)—has risen to its highest level in nearly four years.

Microsoft (MSFT.US) faces a "higher bar" after its rebound! Morgan Stanley remains bullish: Azure growth and Copilot commercialization are key drivers, target price set at $600
Morgan Stanley stated that Microsoft's stock price has recently rebounded, so the tech giant will face a "higher hurdle" if it wants to maintain its upward momentum.

Report: OpenAI plans to accelerate fundraising before Anthropic goes public
OpenAI is racing against time—in order to secure funding ahead of rival Anthropic’s IPO, the company has significantly compressed its fundraising timeline, aiming to complete approximately $30 billion in private financing, which could push its valuation past $1.4 trillion upon completion. Major investors such as SoftBank and MGX are already engaged in discussions. Both AI giants are targeting trillion-dollar valuations, and their largely overlapping investor bases are being forced to make simultaneous bets on both ventures within just a few days.

